Both the GH receptor antagonist pegvisomant and the clinically available dopamine agonists (cabergoline and bromocriptine) seem to have a favourable effect on glucose metabolism; therefore, these drugs could be considered in treating patients with acromegaly and associated glucose imbalance/DM. This evidence concerns the gene GHR and diabetes mellitus.